By contrast, the only phase III trial to date, ATHENA-COMBO, did not show benefit for adding nivolumab to PARP inhibitor maintenance in unselected frontline ovarian cancer, and phase II data in largely pMMR or unselected endometrial cancer have been modest, with benefit confined to biomarker-enriched subgroups. The gene discussed is PARP1; the disease is ovarian cancer.